BioinksBioprintingMedical AMPersonalized MedicineRegenerative Medicine

Ronawk partners with B9Creations on 3D bioprinted hydrogels

Targeting next-gen therapies and personalized medicine applications via Bio-Blocks

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Ronawk, a leader in Advanced Tissue Mimetic Technologies, has named B9Creations its Global Additive Manufacturing Partner, after a joint development effort to automate and mass produce Ronawk’s Bio-Blocks. This is the second high-profile deal in a few days for the DLP 3D printer specialist, after partnering with Poly6 on the use of AM for the production of turbine engines.

B9, which started out by offering a solution focusing on jewelry 3D printing applications and has been focusing on this segment for a long time is now starting to see its technology being implemented in a variety of different areas. In this deal, the company is targeting bioinks with Ronawk. While other methods force cells into an artificial environment, Ronawk’s Bio-Blocks recreate an environment that allows cells to form tissues as they would naturally. The result is tissue that resembles the native architecture and function of tissue in the body. This key advantage is why Bio-Block cells maintain a high level of metabolism, viability, and proliferation which leads to superior output in both quantity and quality of the production of a variety of biologics to drive advancements in human and animal biological therapies, diagnostics, prognostics, and countermeasures to biological threats.

Ronawk partners with B9Creations on 3D bioprinted hydrogels targeting next-gen therapies and personalized medicine via Bio-Blocks “As a biotechnology company with a mission to accelerate next-generation therapies, we needed to partner with a company that is as innovative and agile as we are in order to achieve our potential. B9Creations’ solutions business model and customizable hardware and software toolset enabled our team to move this effort from R&D into production and commercialization which will democratize access to healthcare research worldwide,” said Tom Jantsch, Ronawk President and COO.

Since the 1950s plasticware has been the most common platform scientists use to grow cells. These vessels are 100,000 times stiffer than soft tissue environments like skin, liver, fat, kidney, lungs and the brain, and can only grow in 2D unlike the 3D environment of the body. Since the 1980s, scientists have been able to grow 3D organoid structures utilizing gel-based scaffolds. These scaffolds have a host of issues including being made from animal tumors, inconsistent results that are not repeatable, and are incredibly difficult to scale.

Ronawk partners with B9Creations on 3D bioprinted hydrogels targeting next-gen therapies and personalized medicine via Bio-Blocks

Ronawk’s tissue mimetic substrate enables cells to cultivate microenvironments that streamline the process of growing tissue and cells outside the body in a manner that more closely resembles how cells grow naturally in the body. This enables the flexible introduction of various stimuli and supports the co-culturing of multiple cell types. In addition the process allows for cell isolation and subsequent in-depth cellular signaling analysis while creating an ideal environment for studying cellular functions in real-time by allowing for imaging to take place throughout the process.

The Ronawk Bio-Blocks platform not only empowers researchers to explore heretofore unseen intricacies of stem cell behavior, it also accelerates the pace of drug discovery and the development of tailored therapeutic strategies by offering insights into cellular responses and treatment effects with unprecedented consistency and precision

“Collaboration is critical for turning research advances into commercial therapies rapidly.  The complexity and diversity of modalities is so big that nobody can do it alone. The future of next-generation therapies is not only about discovering them but manufacturing them in a better way.  We needed a company who was responsive, collaborative, and had deep systems expertise in how their hardware, software and our proprietary bio-ink worked together to deliver a solution at scale. Leveraging B9Creations’ technology and consultative services, we produced in 6 hours what we used to produce in a month,” said Ronawk Co-Founder and CTO Heather Decker.

Ronawk partners with B9Creations on 3D bioprinted hydrogels targeting next-gen therapies and personalized medicine via Bio-Blocks

Ronawk is not just advancing; it is setting new standards in the realm of tissue engineering. Where the field typically splits into scaffold-based and scaffold-free approaches, Ronawk confidently marries both approaches into a third method. Its innovative platform empowers cells to start with a scaffold for essential early support, then progress to organically form tissue-like structures that not only mimic but start to organize into functional organ-like structures. This breakthrough facilitates healthier cell growth, authentic cell signaling, and natural formation of tissue microenvironments, significantly boosting the potential of all downstream applications.

“Bioprinting is a key area of focus for B9Creations, developing high-precision, customizable 3D printing solutions that enable next-generation therapies. Our technology partnership with Ronawk is already revolutionizing personalized medicine with root cause analysis of specific cancers at top-tier healthcare institutions, like St. Jude Children’s Research Hospital, leading to targeted, personalized treatment for patients, by enabling cell culture that mimics an in-vivo environment outside the body without the need to continually extract tissue from patients. It’s inspiring and humbling to see the human impact of this technological advancement,” concluded Shon Anderson, B9Creations’ CEO.

Research
Consumer Products AM 2024

1,346 polymer and metal AM companies and 143 end-users. Consumer products AM generated $2.6 billion in 2023. Segment expected to grow to $28 billion by 2033 at 26.8% CAGR. This new market study fro...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.